← Back to Search

Radiopharmaceutical

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (CROSSBOW Trial)

Phase 2
Waitlist Available
Led By Stephan Probst, MD
Research Sponsored by Sir Mortimer B. Davis - Jewish General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months post last dose of rlt
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new treatment for men with advanced prostate cancer who have no other options. The treatment uses a radioactive substance that targets and kills cancer cells. Researchers will see how well this treatment works by measuring changes in a specific cancer marker in the blood.

Eligible Conditions
  • Prostate Cancer
  • Prostate Adenocarcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months post last dose of rlt
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months post last dose of rlt for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Prostate-Specific Antigen
Secondary study objectives
Adverse events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 131I-PSMA-1095 Radioligand Therapy (RLT)Experimental Treatment1 Intervention
Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses

Find a Location

Who is running the clinical trial?

Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor
59 Previous Clinical Trials
21,092 Total Patients Enrolled
16 Trials studying Prostate Cancer
3,594 Patients Enrolled for Prostate Cancer
Stephan Probst, MDPrincipal InvestigatorJewish General Hospital
1 Previous Clinical Trials
2,000 Total Patients Enrolled
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top